{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2024,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":2024,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"295742b6fa46","filters":{"topic":"CAR-T cell therapy research"}},"results":[{"id":"W2787301955","doi":"10.1056/nejmoa1709866","title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5641,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Lymphoblastic Leukemia; Medicine; Leukemia; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.008970916473494756,"gpt":0.2580174046244769,"spread":0.2490464881509822,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007485023,0.0001644597,0.0004783413,0.0003559602,0.00003616726,0.00001029158,0.0001143665,0.00007123092,0.001037408],"category_scores_gemma":[0.0001772277,0.00009854275,0.0000311583,0.0002964392,0.0002912947,0.00007583806,0.00002446688,0.0004217398,0.000008140611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000172032,"about_ca_system_score_gemma":0.0004433873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006502065,"about_ca_topic_score_gemma":0.0002833824,"domain_scores_codex":[0.9984068,0.00006961104,0.0004155744,0.0001764182,0.0006447802,0.0002867734],"domain_scores_gemma":[0.9988749,0.0001229044,0.000166079,0.0001786892,0.0002205353,0.0004368801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01994646,0.000186928,0.503536,0.0001065777,0.0002472322,0.001104037,0.006881388,0.000007506688,0.0700179,0.00001471024,0.007882032,0.3900692],"study_design_scores_gemma":[0.3168774,0.01970884,0.6209462,0.002458517,0.000288554,0.02575346,0.0004982126,0.0002952302,0.006135383,0.0001335618,0.006650976,0.0002536392],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926869,0.001588785,0.0001586982,0.00107545,0.0001631842,0.0002267123,9.671351e-7,0.000008426132,0.004090901],"genre_scores_gemma":[0.9914851,0.0008854503,0.0003786037,0.0002907307,0.004197399,8.530593e-7,0.000003623548,0.00002842769,0.002729878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3898156,"threshold_uncertainty_score":0.9998758,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2903062212","doi":"10.1056/nejmoa1804980","title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4044,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Neutropenia; Internal medicine; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Lymphoma; Refractory (planetary science); Transplantation; Gastroenterology; Febrile neutropenia; Rituximab; Clinical endpoint; Oncology; Phases of clinical research; Salvage therapy; Immunology; Immunotherapy; Chimeric antigen receptor; Chemotherapy; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02608030782430969,"gpt":0.3167913150251551,"spread":0.2907110072008454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001722337,0.0002232788,0.0007384598,0.0005726768,0.00005644924,0.00001127936,0.0002495496,0.0001596681,0.006417438],"category_scores_gemma":[0.001325435,0.0001338626,0.0001030553,0.0005094261,0.0002093292,0.0001183952,0.00004330706,0.0006261265,0.00006333677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002442312,"about_ca_system_score_gemma":0.0006421408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001920296,"about_ca_topic_score_gemma":0.0003956351,"domain_scores_codex":[0.9971784,0.0002052087,0.0008389946,0.000221123,0.001060194,0.0004961312],"domain_scores_gemma":[0.9977019,0.0004188839,0.0003138324,0.0003856965,0.000529125,0.0006505487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03608234,0.004462364,0.01219038,0.0001911882,0.0002149219,0.00664496,0.008884333,4.070164e-7,0.2546434,0.00005965592,0.08809042,0.5885356],"study_design_scores_gemma":[0.485451,0.01306875,0.0122306,0.001114607,0.0001481276,0.002910323,0.0007313819,0.0001264256,0.007791921,0.0001523997,0.4760789,0.0001955194],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785358,0.001134369,0.0001817628,0.006129332,0.0008561048,0.0002530699,0.000002519827,0.00002025536,0.0128868],"genre_scores_gemma":[0.9560993,0.001995262,0.0004294145,0.00211478,0.009333962,0.000001792151,0.000005787499,0.00005323259,0.02996652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5883401,"threshold_uncertainty_score":0.9944908,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3133229959","doi":"10.1056/nejmoa2024850","title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2424,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Chimeric antigen receptor; Refractory (planetary science); Multiple myeloma; Antigen; Cancer research; Medicine; Receptor; T cell; Internal medicine; Immunology; Biology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.03150045003787461,"gpt":0.317176045044978,"spread":0.2856755950071034,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00135701,0.0001378534,0.0005851484,0.0003116011,0.00002896602,0.000009096439,0.00008419499,0.00009405542,0.002156265],"category_scores_gemma":[0.001730147,0.00009736062,0.00006195412,0.0003423826,0.0001087494,0.00006359041,0.00003651131,0.0007361601,0.000004530305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000104254,"about_ca_system_score_gemma":0.0004184455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009808112,"about_ca_topic_score_gemma":0.0001749127,"domain_scores_codex":[0.9981605,0.0001717555,0.0005893305,0.0001731906,0.0006571335,0.0002481199],"domain_scores_gemma":[0.9983024,0.0005559504,0.000161919,0.0002251544,0.000281102,0.0004734875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002363184,0.0001199379,0.03945789,0.00005696085,0.00008704776,0.004774373,0.001481868,0.000005023704,0.5668801,0.0000149823,0.003404499,0.3813541],"study_design_scores_gemma":[0.2537316,0.004298514,0.2752876,0.001789942,0.0001884467,0.01428266,0.00144151,0.0002627424,0.03862162,0.0006407821,0.4092073,0.0002473057],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742563,0.008804465,0.00006877605,0.0133037,0.0003462434,0.0001129951,8.733201e-7,0.000008193773,0.003098496],"genre_scores_gemma":[0.9861068,0.003239778,0.0007677185,0.0009132765,0.002773772,8.551771e-7,0.000004736647,0.00002624246,0.006166843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5282585,"threshold_uncertainty_score":0.9987559,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3176532045","doi":"10.1016/s0140-6736(21)00933-8","title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1664,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Chimeric antigen receptor; Antigen; Refractory (planetary science); Medicine; Open label; Multiple myeloma; Receptor; Immunology; Cell; Immunotherapy; Cancer research; Biology; Internal medicine; Immune system; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.06200547005268376,"gpt":0.3469799739780643,"spread":0.2849745039253806,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008030905,0.0004032412,0.001006406,0.0001658178,0.0002338401,0.0001875513,0.00068,0.0001418072,0.001824109],"category_scores_gemma":[0.0001563703,0.0002529098,0.00006003565,0.001407882,0.0001032169,0.0002579718,0.0002165818,0.0007384444,0.0001047507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002093314,"about_ca_system_score_gemma":0.0005457744,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000240328,"about_ca_topic_score_gemma":0.0003413624,"domain_scores_codex":[0.9963062,0.0007694658,0.0005554862,0.0007643322,0.0008880896,0.0007163756],"domain_scores_gemma":[0.9974074,0.000231398,0.0002505707,0.001532803,0.0003970627,0.0001807323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.06173945,0.04167672,0.1457231,0.00009114985,0.0003762402,0.0002872868,0.004616629,0.000005773772,0.711747,0.000001036244,0.007687887,0.02604774],"study_design_scores_gemma":[0.3286624,0.01421707,0.4873197,0.000271487,0.00008636002,0.00001641603,0.001185607,0.001058705,0.1238857,0.000005522557,0.04249538,0.0007956207],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992383,0.0007411539,0.00001219705,0.0005855665,0.0002050781,0.004241194,0.00006735212,0.0001856816,0.001578763],"genre_scores_gemma":[0.9885854,0.001284602,0.001564609,0.0006853468,0.0003316656,0.0002516014,0.000395695,0.0001201218,0.006781036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5878613,"threshold_uncertainty_score":0.9999923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1963522404","doi":"10.1182/blood-2011-10-384388","title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1445,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"CD19; Medicine; Chimeric antigen receptor; Cytokine; Cytokine release syndrome; Adoptive cell transfer; Immunology; Cell therapy; T cell; Ex vivo; Antigen; Cancer research; In vivo; Cell; Immune system; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.05428349638532947,"gpt":0.3184524654414508,"spread":0.2641689690561213,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000983645,0.0001687097,0.0007398141,0.0001682093,0.00002661798,0.000003782792,0.0001198169,0.0002136439,0.0004563281],"category_scores_gemma":[0.0001687316,0.0001364429,0.0001525133,0.0004466082,0.000177283,0.00004470427,0.00003584481,0.0003202643,0.000003148085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000164953,"about_ca_system_score_gemma":0.0002189924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005169609,"about_ca_topic_score_gemma":0.00007298506,"domain_scores_codex":[0.9978631,0.0002766708,0.0008085643,0.0003460982,0.0004073275,0.0002982841],"domain_scores_gemma":[0.9988495,0.0001913278,0.0002892262,0.0003529716,0.0001434649,0.0001734973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01045744,0.006121028,0.1594733,0.0000796713,0.0001417334,0.00002806424,0.0005272293,2.128374e-7,0.8225816,0.000003770029,0.00002590406,0.000560056],"study_design_scores_gemma":[0.07727594,0.003422469,0.1811591,0.000254516,0.0001467954,0.000007841009,0.00006546103,0.00001029276,0.7374966,0.000007185417,0.00003373436,0.0001201095],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973534,0.0001511948,0.00002222568,0.00003104029,0.00007785418,0.0009910261,0.00002331608,0.00002396501,0.001326011],"genre_scores_gemma":[0.9979069,0.0008659053,0.00087389,0.00001915359,0.00005541556,0.00001327311,0.00001769719,0.00003290785,0.0002148052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08508501,"threshold_uncertainty_score":0.5563981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2763751953","doi":"10.1158/2159-8290.cd-17-0698","title":"Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1364,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Juno Therapeutics","keywords":"Neurotoxicity; Medicine; Cytokine release syndrome; Immunology; Bone marrow; Blood–brain barrier; Pericyte; Endothelium; Chimeric antigen receptor; Cancer research; Immunotherapy; Endothelial stem cell; Internal medicine; Central nervous system; Immune system; Toxicity; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01706914031407214,"gpt":0.3043987147974286,"spread":0.2873295744833565,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001690933,0.0001979742,0.000282663,0.0001067953,0.0001266251,0.000183354,0.0001179912,0.00009117803,0.0004326929],"category_scores_gemma":[0.00003544825,0.0001561088,0.00006110157,0.0000751406,0.0002712747,0.0006827267,0.00005490631,0.0003198211,0.000003098399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000180566,"about_ca_system_score_gemma":0.0002133049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001087326,"about_ca_topic_score_gemma":0.0004809887,"domain_scores_codex":[0.9987343,0.00006827261,0.0001668963,0.0003995792,0.000323186,0.000307786],"domain_scores_gemma":[0.9991278,0.00007166412,0.0001096098,0.0005379993,0.00005600739,0.00009693399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0057017,0.00009823489,0.1093533,0.00005715216,0.00008337406,0.00005833022,0.0007839753,0.00001301092,0.8776358,0.00001689944,0.00003672804,0.006161468],"study_design_scores_gemma":[0.005775846,0.0004905535,0.4691498,0.0003029887,0.00003607905,0.00001328487,0.0001391776,0.00005137812,0.521816,0.00005186816,0.001949041,0.0002239744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968907,0.0001953699,0.0001191685,0.0008432292,0.000124087,0.000964308,0.00009117692,0.0000164705,0.0007554797],"genre_scores_gemma":[0.9914401,0.0007502206,0.00003823792,0.000628761,0.0003103473,0.0003688697,0.000008831924,0.0000484792,0.006406134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3597965,"threshold_uncertainty_score":0.636593,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4206716689","doi":"10.1126/science.abm0594","title":"CAR T cells produced in vivo to treat cardiac injury","year":2022,"lang":"en","type":"article","venue":"Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1241,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute","keywords":"In vivo; Chimeric antigen receptor; Cardiac fibrosis; Fibrosis; Cardiac function curve; Ex vivo; Antigen; Messenger RNA","retraction":null,"screen_n_in":null,"score":{"opus":0.02245622904933814,"gpt":0.3354162901594916,"spread":0.3129600611101535,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001331358,0.00007029633,0.0001548733,0.0003655348,0.000163409,0.00002284373,0.0003120076,0.00001201473,0.002285717],"category_scores_gemma":[0.00009648245,0.00006426802,0.00003945325,0.002265681,0.0001653409,0.0000642447,0.0002827462,0.0002034531,0.00006221653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005049471,"about_ca_system_score_gemma":0.0005480439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001728229,"about_ca_topic_score_gemma":0.000005084531,"domain_scores_codex":[0.9980599,0.00005899927,0.0001092416,0.000435515,0.0009321754,0.0004041117],"domain_scores_gemma":[0.9992185,0.00002600949,0.0000133649,0.0004863854,0.00006131297,0.0001944023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001015197,0.00004545006,0.004826482,0.000007747376,0.000001164689,0.00002015822,0.001097653,0.00003168678,0.983887,0.0000114009,0.001882707,0.008087097],"study_design_scores_gemma":[0.0002128175,0.0004021507,0.003045146,0.000006111312,0.000002935808,0.000004637512,0.0003918729,0.00003678429,0.9298099,0.0000135318,0.066,0.00007406869],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881242,0.0000592224,7.44021e-7,0.001090521,0.00035199,0.0006176165,0.0000155455,0.00002478803,0.009715394],"genre_scores_gemma":[0.9743063,0.00001151841,0.000097884,0.0003818581,0.00008510504,0.0001017296,7.167647e-7,0.00001067767,0.02500417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06411729,"threshold_uncertainty_score":0.9986264,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2345568581","doi":"10.1186/s12916-016-0623-5","title":"Cancer immunotherapy: the beginning of the end of cancer?","year":2016,"lang":"en","type":"review","venue":"BMC Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1192,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Oncolytic virus; Medicine; Immunotherapy; Cancer immunotherapy; Cancer; Adoptive cell transfer; Immune system; Immune checkpoint; Monoclonal antibody; Immunology; Cytotoxic T cell; Cancer research; Antibody; T cell; Biology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1089515662707683,"gpt":0.4438961115139246,"spread":0.3349445452431563,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00135912,0.0004150455,0.002521362,0.0002038483,0.00006412641,0.000003437867,0.0008740386,0.0002383551,0.01133299],"category_scores_gemma":[0.0003256736,0.0001453585,0.0006678543,0.0007530347,0.001518964,0.00001954205,0.0001469064,0.0006821399,0.000006044244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003154916,"about_ca_system_score_gemma":0.002340377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002316317,"about_ca_topic_score_gemma":0.000255889,"domain_scores_codex":[0.9965782,0.0003962917,0.001050651,0.000373644,0.001199001,0.0004022061],"domain_scores_gemma":[0.9957756,0.001274748,0.0009212157,0.001654213,0.0002753922,0.00009879396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001110672,0.00002828298,0.0005134141,0.01314512,0.0007506499,0.000002462036,0.0003272571,2.214476e-7,0.00144283,0.00009455609,0.003141365,0.9804428],"study_design_scores_gemma":[0.001376003,0.0001602575,0.0002851518,0.0861817,0.0009262197,0.0000290976,0.0000638801,0.000001655605,0.0002037148,0.00002111685,0.9106293,0.0001219591],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009592086,0.9918358,0.00001736847,0.002194832,0.0008560384,0.001954842,0.00006020511,0.00002566614,0.002959363],"genre_scores_gemma":[0.0000953279,0.9793103,0.00001665431,0.0002252489,0.001686662,0.0003422188,0.000008064556,0.0001388792,0.01817667],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9803208,"threshold_uncertainty_score":0.9895708,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2756071038","doi":"10.1182/blood-2017-06-793141","title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1112,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Juno Therapeutics; National Institutes of Health","keywords":"Chimeric antigen receptor; Cytokine release syndrome; CD19; Immunology; Receptor; Antigen; Medicine; Cell therapy; Cytokine; Immunotherapy; Cancer research; Biology; Cell; Immune system; Internal medicine; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.02149768403193765,"gpt":0.2764908282456986,"spread":0.254993144213761,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001916821,0.0002098351,0.0004162679,0.0001369483,0.00009341918,0.00004359379,0.0002313801,0.0001374252,0.001794618],"category_scores_gemma":[0.00006143269,0.0001779006,0.0001164175,0.0001149503,0.0002948671,0.00007124786,0.0001079062,0.0001899708,0.00002726802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001247247,"about_ca_system_score_gemma":0.00005793185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001397663,"about_ca_topic_score_gemma":0.000005014746,"domain_scores_codex":[0.9985998,0.00005942796,0.0002642382,0.0003518452,0.0003886209,0.0003361084],"domain_scores_gemma":[0.9984493,0.00005254627,0.0001571508,0.001012733,0.0001054195,0.0002228968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.001598242,0.001053786,0.06346476,0.0001521596,0.000394395,0.0002288345,0.0001852459,2.87388e-7,0.9233755,0.000002612182,0.0003969585,0.009147156],"study_design_scores_gemma":[0.01750686,0.002322863,0.5160027,0.0002000851,0.0001680306,0.0004982947,0.00007238649,0.00002431619,0.4565747,0.00004659985,0.006198857,0.0003842786],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890479,0.002050728,0.000004354756,0.0003848938,0.00008760545,0.0005884854,0.00004123591,0.00003153317,0.007763242],"genre_scores_gemma":[0.9920476,0.003640353,0.0005804933,0.00008704815,0.00009106987,0.00002451755,0.00001916791,0.00005587528,0.003453855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4668008,"threshold_uncertainty_score":0.9991179,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4207068215","doi":"","title":"CAR T Cells Produced in vivo to Treat Cardiac Injury","year":2023,"lang":"en","type":"article","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":940,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"In vivo; Spleen; Chimeric antigen receptor; Messenger RNA; Fibrosis; Ex vivo; Antigen; Cardiac fibrosis; Immunology; Cell biology; Cancer research; Biology; Medicine; T cell; Pathology; Immune system; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01940363644517919,"gpt":0.2824189550589764,"spread":0.2630153186137972,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00440023,0.0001849393,0.0003450421,0.0004757897,0.0001271908,0.00008678381,0.0004044727,0.0001076836,0.0008876223],"category_scores_gemma":[0.0009294039,0.0001865545,0.0001425811,0.001830551,0.00009803496,0.00007671575,0.0003049398,0.0003035937,0.0004479584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000213213,"about_ca_system_score_gemma":0.0002145826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00110159,"about_ca_topic_score_gemma":0.0003700551,"domain_scores_codex":[0.9960945,0.002017421,0.0003219271,0.0005697563,0.0005122687,0.000484163],"domain_scores_gemma":[0.9965442,0.0006640911,0.00006250686,0.001619174,0.000815092,0.0002948955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0000746562,0.0002079702,0.007252497,0.00006439461,0.00002209281,0.00001583968,0.005818116,0.000006635409,0.9404578,0.0006862337,0.009884249,0.03550951],"study_design_scores_gemma":[0.0005769987,0.000001847118,0.005410927,0.0003139835,0.00001501273,0.000002706035,0.0001936308,0.0004091032,0.9189836,0.00006519201,0.07385924,0.0001677664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9347064,0.0001203658,0.0001265515,0.01279943,0.0001366013,0.0009176094,0.00004215898,0.0002517398,0.05089918],"genre_scores_gemma":[0.8249031,0.0004887977,0.001673659,0.0001844644,0.00005370414,0.0001570352,0.0001066583,0.00006899631,0.1723636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1214644,"threshold_uncertainty_score":0.9718841,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2805523469","doi":"10.1158/2159-8290.cd-17-1319","title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Emerald Foundation; Parker Institute for Cancer Immunotherapy; Alberta Emerald Foundation; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; Juno Therapeutics; Leukemia and Lymphoma Society; American Society of Hematology","keywords":"Lymphoblastic Leukemia; Neurotoxicity; Medicine; Leukemia; Cell; Cancer research; Oncology; Immunology; Biology; Internal medicine; Toxicity; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02659625784607731,"gpt":0.3056077702695786,"spread":0.2790115124235013,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002206867,0.0002060785,0.0005290411,0.00008192606,0.00003881809,0.00002062434,0.0001150412,0.0001685047,0.0001805022],"category_scores_gemma":[0.00005016895,0.0001244923,0.00006323906,0.0003186906,0.0008998015,0.0001124884,0.00005529641,0.0003173231,0.000003072337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002284368,"about_ca_system_score_gemma":0.0005177131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001413289,"about_ca_topic_score_gemma":0.00007843931,"domain_scores_codex":[0.9984147,0.0001476359,0.0003335702,0.000432053,0.0003337624,0.0003383059],"domain_scores_gemma":[0.998982,0.0002733958,0.0001558797,0.0002734353,0.0001822609,0.0001330578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008759233,0.0005998213,0.9795348,0.00002138474,0.0001455091,0.00002089546,0.0001198438,0.000009137339,0.00917459,0.000001804559,0.00009245255,0.001520545],"study_design_scores_gemma":[0.01624948,0.008924246,0.9650727,0.000199686,0.00006036351,0.000001795143,0.00002986605,0.0001356484,0.00908043,0.000009789634,0.00007082629,0.0001651789],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982314,0.0002243147,0.00001849296,0.00002340413,0.00009849584,0.0007943697,0.00005988787,0.00001918468,0.0005304862],"genre_scores_gemma":[0.997807,0.0008901278,0.00001831794,0.0002430613,0.00008064821,0.00004118559,0.00002918579,0.00003397683,0.000856546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0144621,"threshold_uncertainty_score":0.5076647,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2053967595","doi":"10.1084/jem.20091918","title":"Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","year":2010,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":887,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research; Howard Hughes Medical Institute; University College London; Swim Across America; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute","keywords":"Cytotoxic T cell; Adoptive cell transfer; Cancer research; Biology; CD8; Melanoma; Interleukin 21; Immunology; Antigen; In vitro; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01306096873143876,"gpt":0.303891093591667,"spread":0.2908301248602283,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001786586,0.0003172861,0.0007159737,0.0002825072,0.0001467517,0.00002634988,0.0003094717,0.0001125237,0.004504736],"category_scores_gemma":[0.0001425001,0.0001822137,0.0001083127,0.0003626998,0.0006334383,0.000312927,0.0001032472,0.001082307,0.00001781142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002451991,"about_ca_system_score_gemma":0.0003029847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001649813,"about_ca_topic_score_gemma":0.00004179596,"domain_scores_codex":[0.9975953,0.0002381897,0.0005306564,0.0002434948,0.0009309822,0.0004613847],"domain_scores_gemma":[0.9983098,0.00035189,0.0001702993,0.0004117087,0.0002394756,0.0005168472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006193503,0.0004079499,0.001638861,0.00002737192,0.0002099431,0.0003537506,0.008896226,6.873054e-8,0.9795902,0.0000136409,0.0003503047,0.002318119],"study_design_scores_gemma":[0.008437872,0.002167391,0.02555592,0.0002033374,0.0001694553,0.002903611,0.002715142,0.00002444462,0.9539281,0.0000334326,0.003676707,0.0001846141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993064,0.001992454,0.00008654485,0.002664246,0.0005206721,0.0006074596,0.00000484016,0.00001561051,0.001044203],"genre_scores_gemma":[0.9973286,0.0002450846,0.0001852533,0.0009208108,0.0006691876,0.00002138934,0.000002417837,0.00005634242,0.0005709135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02566219,"threshold_uncertainty_score":0.9964053,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1877911682","doi":"10.1038/nm.3910","title":"NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","year":2015,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":848,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Carleton University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Cytotoxic T cell; Antigen; Medicine; Multiple myeloma; Immunology; T-cell receptor; Chimeric antigen receptor; Cancer research; Bone marrow; T cell; Immune system; Biology; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.0176906565937794,"gpt":0.2984853652944252,"spread":0.2807947087006458,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002089701,0.0006395729,0.001416432,0.00136148,0.00007483766,0.00003449743,0.0005165967,0.0008069148,0.001629798],"category_scores_gemma":[0.0008626478,0.000491093,0.0001708226,0.002334805,0.0004377041,0.0001489196,0.0001311151,0.002944758,0.0002493742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007013414,"about_ca_system_score_gemma":0.0003681491,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004415311,"about_ca_topic_score_gemma":0.00002589775,"domain_scores_codex":[0.9945096,0.0002697208,0.0008058513,0.0009535852,0.002198705,0.001262485],"domain_scores_gemma":[0.9962656,0.0006253083,0.0001524674,0.001214114,0.0006732654,0.0010692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002865624,0.0004818672,0.00490857,0.0004773799,0.0001566118,0.00764302,0.002172702,0.0000192364,0.8056148,0.001232293,0.154388,0.02003996],"study_design_scores_gemma":[0.03101563,0.00282616,0.04629044,0.001270148,0.00006501681,0.0003862865,0.001570367,0.0004310898,0.2013193,0.0005635001,0.7134046,0.0008574751],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9062638,0.06310382,0.0002570635,0.008097109,0.004262364,0.002882053,0.00001451235,0.0003809771,0.01473833],"genre_scores_gemma":[0.9818885,0.004986143,0.0006582647,0.001111906,0.003702494,0.00006373681,0.0002076104,0.0001760618,0.007205292],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6042955,"threshold_uncertainty_score":0.9997541,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989273697","doi":"10.1172/jci32103","title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":835,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; School of Medicine, Stanford University; National Heart, Lung, and Blood Institute; School of Medicine, Oregon Health and Science University; National Cancer Institute; National Institutes of Health; National Center for Research Resources; Cancer Research Institute","keywords":"Adoptive cell transfer; Cytotoxic T cell; Biology; CD8; Effector; Immunology; T cell; Immunotherapy; Antigen; Cell biology; Immune system; In vitro; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.07917265780015434,"gpt":0.3354791466112934,"spread":0.256306488811139,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001725846,0.0002271134,0.001126633,0.0002560324,0.00004406785,0.00001856154,0.0002303376,0.0003030563,0.000809481],"category_scores_gemma":[0.0006313491,0.0001856783,0.0007538074,0.0002393856,0.0006549574,0.0002962101,0.00003065015,0.001084697,0.00001666258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001748324,"about_ca_system_score_gemma":0.0008389903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001604713,"about_ca_topic_score_gemma":0.0000177708,"domain_scores_codex":[0.9955803,0.0007251053,0.002087693,0.0002908188,0.0009518571,0.0003641894],"domain_scores_gemma":[0.9961279,0.001946402,0.0005553173,0.0002761117,0.0005034066,0.0005908688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00207448,0.0007062325,0.04299587,0.0001910857,0.0001797018,0.0001829741,0.002678032,0.0006591702,0.9481181,0.000001243457,0.0006707695,0.001542364],"study_design_scores_gemma":[0.006026975,0.001728483,0.1556273,0.0003859039,0.0002122034,0.00002751195,0.0006181215,0.0007647097,0.8342811,0.00004513247,0.000133684,0.0001488735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969844,0.0005033549,0.00009851745,0.0005403641,0.0006630173,0.0005425514,0.00001911208,0.0000119522,0.0006367349],"genre_scores_gemma":[0.9943975,0.001109096,0.00309327,0.0003393505,0.0005977594,0.000004060553,0.00001929067,0.0000362221,0.0004034417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1138369,"threshold_uncertainty_score":0.8863249,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2807637103","doi":"10.1200/jco.2018.77.8084","title":"T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":791,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"NIH Clinical Center; National Cancer Institute; National Institutes of Health; Kite Pharma; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Chimeric antigen receptor; Multiple myeloma; Minimal residual disease; Cytokine release syndrome; Antigen; Cyclophosphamide; Bone marrow; Fludarabine; Immunology; Regimen; Cancer research; Internal medicine; T cell; Oncology; Chemotherapy; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.1424856689320132,"gpt":0.4582241318970513,"spread":0.3157384629650381,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003521192,0.0002489644,0.001725144,0.00034952,0.0001082403,0.00002335334,0.0005121107,0.0007003599,0.001717882],"category_scores_gemma":[0.003317806,0.0001915046,0.0005177273,0.0004888546,0.0004915545,0.000162569,0.0001476259,0.001080789,0.00008814525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001162619,"about_ca_system_score_gemma":0.001434802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004364363,"about_ca_topic_score_gemma":0.00001965836,"domain_scores_codex":[0.9940622,0.001096804,0.002996368,0.0004529663,0.0008832754,0.0005083808],"domain_scores_gemma":[0.9932472,0.001813929,0.001472527,0.0005508784,0.001683524,0.001231918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0102096,0.002464964,0.02329128,0.00003317707,0.0002544784,0.0001138603,0.0004073669,0.00003135172,0.9077067,0.000004732919,0.007632538,0.04784992],"study_design_scores_gemma":[0.009864193,0.03322637,0.2479816,0.0002179764,0.0002488729,0.0001167019,0.0002517743,0.001635585,0.6436263,0.00004104456,0.06248765,0.000301946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918557,0.0001394268,0.0008930776,0.003106453,0.001353845,0.0007209603,0.00001452482,0.00002301307,0.001893033],"genre_scores_gemma":[0.9564465,0.001375453,0.03792319,0.0009845967,0.002118967,0.000007085034,0.00001053587,0.00005780108,0.001075878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2640804,"threshold_uncertainty_score":0.9991947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379375986","doi":"10.1056/nejmoa2303379","title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":733,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Lenalidomide; Multiple myeloma; Refractory (planetary science); Standard of care; Medicine; Internal medicine; Oncology; Biology; Astrobiology","retraction":null,"screen_n_in":null,"score":{"opus":0.0463347515928686,"gpt":0.3503627163535822,"spread":0.3040279647607136,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00206058,0.0002126741,0.0008818388,0.000898416,0.00004926935,0.00001287796,0.0002164036,0.0001231794,0.004112072],"category_scores_gemma":[0.002297341,0.0001269556,0.000128873,0.0008456879,0.000141524,0.0001026303,0.00004731263,0.0009529152,0.00003313168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003443723,"about_ca_system_score_gemma":0.0009327835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002117187,"about_ca_topic_score_gemma":0.00065987,"domain_scores_codex":[0.9969401,0.0001854835,0.0008109018,0.0002031955,0.001405785,0.0004545144],"domain_scores_gemma":[0.9974999,0.0009403994,0.0002286104,0.0002981931,0.0004715848,0.0005613175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03627357,0.00008413017,0.03605159,0.0002551143,0.00020817,0.008088185,0.009405449,0.00006186545,0.09386331,0.000009889037,0.04742233,0.7682764],"study_design_scores_gemma":[0.1885855,0.008762415,0.02786107,0.00171624,0.0001309514,0.001725619,0.005047374,0.00009527098,0.004570797,0.0001281578,0.761182,0.0001945944],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809995,0.003704969,0.00007307681,0.01053792,0.0008796266,0.0003816111,0.00001034268,0.00004464995,0.003368333],"genre_scores_gemma":[0.9802246,0.003126203,0.000234546,0.000490355,0.005864019,0.000003792894,0.00002178794,0.00005458501,0.009980117],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7680818,"threshold_uncertainty_score":0.9967983,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4319812103","doi":"10.1056/nejmoa2213614","title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":705,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Celgene; Bristol-Myers Squibb","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Oncology; Internal medicine; Lenalidomide; Materials science; Metallurgy","retraction":null,"screen_n_in":null,"score":{"opus":0.0453368430261291,"gpt":0.3410931074954077,"spread":0.2957562644692786,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002576751,0.0001615625,0.000682764,0.0006997898,0.00004132199,0.000009548,0.0001136044,0.0001056615,0.001452142],"category_scores_gemma":[0.002374972,0.00009719752,0.00005683736,0.0006178869,0.0001589584,0.00006919604,0.00003908023,0.0008094397,0.00001082896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001473899,"about_ca_system_score_gemma":0.0004177111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001147194,"about_ca_topic_score_gemma":0.0002105755,"domain_scores_codex":[0.9977756,0.0001516697,0.0006314427,0.0001797012,0.0009241317,0.0003375204],"domain_scores_gemma":[0.9978679,0.001003844,0.0001979745,0.000232686,0.000204155,0.0004933816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03526956,0.0001214862,0.07603589,0.0002038199,0.0002435687,0.010216,0.006509895,0.00001679672,0.2092744,0.00003071779,0.08841035,0.5736675],"study_design_scores_gemma":[0.2461434,0.01271051,0.1230569,0.002255801,0.0001513475,0.004296582,0.002036703,0.0002367223,0.003129611,0.000496697,0.6052576,0.0002281194],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9782991,0.001621545,0.00003552756,0.01764884,0.0004043725,0.00024827,0.000003045299,0.00002935019,0.001709984],"genre_scores_gemma":[0.9727142,0.00460259,0.0003351364,0.0004815767,0.002943418,0.000002228262,0.000007003017,0.00004330995,0.01887053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5734394,"threshold_uncertainty_score":0.9994606,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2910164268","doi":"10.1158/1078-0432.ccr-18-0432","title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":672,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Deutsche Krebshilfe","keywords":"Cancer; Antigen; Medicine; Cancer research; Solid tumor; Pathology; Immunology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1480627897940606,"gpt":0.497207940263481,"spread":0.3491451504694204,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01206825,0.000493136,0.001605039,0.0004776772,0.0003634584,0.000180812,0.0006691451,0.0005957026,0.00333136],"category_scores_gemma":[0.002659652,0.0004238976,0.0005544425,0.001371895,0.001193161,0.0002350091,0.0008277033,0.004511038,0.0003507452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00051293,"about_ca_system_score_gemma":0.003054891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001131936,"about_ca_topic_score_gemma":0.0002001922,"domain_scores_codex":[0.9897418,0.002169554,0.001605605,0.001922407,0.002433484,0.002127166],"domain_scores_gemma":[0.99078,0.005341197,0.000333242,0.001130915,0.0009744923,0.00144013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004396376,0.0008500959,0.6721124,0.0007020161,0.0002465571,0.0003221736,0.0001841426,0.00004701467,0.1936791,0.00000780114,0.01127073,0.1161815],"study_design_scores_gemma":[0.01802466,0.006515795,0.8512455,0.001424759,0.0002192344,0.0000481983,0.0009443463,0.0068663,0.07905229,0.0002894633,0.03352242,0.00184698],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853399,0.003253832,0.00001121431,0.005847967,0.0007036951,0.002815039,0.00008756288,0.0001104155,0.001830327],"genre_scores_gemma":[0.9643725,0.02332008,0.0001365617,0.0008407559,0.002875477,0.000290526,0.00001821236,0.0001530063,0.007992871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1791331,"threshold_uncertainty_score":0.9998213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281714381","doi":"10.1200/jco.22.00842","title":"Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Gastroenterology; Cytokine release syndrome; Progression-free survival; Oncology; Chimeric antigen receptor; Surgery; Immunotherapy; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1053813735833881,"gpt":0.4275996332850936,"spread":0.3222182597017055,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006861262,0.0003432141,0.001980298,0.0003779603,0.0003750529,0.00004230504,0.0006530831,0.0005373737,0.004189357],"category_scores_gemma":[0.00119618,0.0002896674,0.001140627,0.0004487903,0.0002323995,0.0003187422,0.0001751996,0.002321329,0.00005448308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004658435,"about_ca_system_score_gemma":0.003074835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004532814,"about_ca_topic_score_gemma":0.00002323575,"domain_scores_codex":[0.9931665,0.001574675,0.002788658,0.0005926219,0.001194252,0.0006832584],"domain_scores_gemma":[0.9935372,0.002158103,0.00213883,0.0006356935,0.000820089,0.0007101148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04370902,0.00835889,0.0572143,0.00007416298,0.0006110329,0.0003038065,0.0008911008,0.0001305585,0.7406034,0.00001166397,0.03357917,0.1145129],"study_design_scores_gemma":[0.04173625,0.04750365,0.08018192,0.00002589242,0.0001660369,0.0001637044,0.0008610908,0.0006464586,0.01906875,0.00005061588,0.8092293,0.0003663344],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877518,0.001820263,0.0002293019,0.002171722,0.00455906,0.001344877,0.00004677721,0.00005148336,0.002024681],"genre_scores_gemma":[0.9775819,0.005032242,0.005973665,0.001573749,0.002743393,0.00005958544,0.0001068133,0.0001235162,0.006805128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7756501,"threshold_uncertainty_score":0.9999803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2068343048","doi":"10.1182/blood-2013-11-536433","title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":617,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Concordance; Lymphoma; Diffuse large B-cell lymphoma; Gene expression profiling; Germinal center; Pathology; Cancer research; Medicine; Computational biology; Biology; Molecular biology; B cell; Gene expression; Gene; Immunology; Internal medicine; Antibody; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02536204904560638,"gpt":0.3065655540313091,"spread":0.2812035049857027,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000550974,0.0001928511,0.000558424,0.0002718052,0.00004208473,0.00001067188,0.0001864748,0.0001657178,0.0001800007],"category_scores_gemma":[0.00008235472,0.0001743039,0.00009902279,0.0002734518,0.00005626727,0.00008012982,0.000115112,0.0001409885,0.00001004412],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003705401,"about_ca_system_score_gemma":0.000130401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004855853,"about_ca_topic_score_gemma":0.000014802,"domain_scores_codex":[0.9981138,0.0001377157,0.0005536761,0.0002901783,0.000444321,0.0004603846],"domain_scores_gemma":[0.9988384,0.0001816282,0.0002246708,0.0005211393,0.00009338899,0.0001408323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002501161,0.003947221,0.03558208,0.0003124327,0.00001707237,0.00003751345,0.0009667765,0.0000125171,0.9558092,0.000007594942,0.000009089887,0.003048402],"study_design_scores_gemma":[0.02347867,0.0004409885,0.00235774,0.0002203596,0.00007435823,0.00002282709,0.0001145033,0.002608667,0.9700204,0.00001732695,0.0004886932,0.0001555379],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971153,0.0004691923,0.0007079066,0.000008383644,0.00007669683,0.0003745795,0.000008116524,0.0000288057,0.001211063],"genre_scores_gemma":[0.9890652,0.0000566526,0.01011685,0.00002620021,0.0001195845,0.00001248814,0.00001648628,0.00005033995,0.0005362013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03322434,"threshold_uncertainty_score":0.7107908,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787578932","doi":"10.1038/nm.4478","title":"A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":600,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; T-cell receptor; CD28; Cell biology; Signal transduction; T cell; Biology; STAT5; Cytokine; Cancer research; Antigen; Immunology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01387323653574358,"gpt":0.3217982719610501,"spread":0.3079250354253065,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001516007,0.0004792845,0.001120652,0.0005532246,0.0002534024,0.00003145836,0.0003389255,0.0004939444,0.006188303],"category_scores_gemma":[0.001911207,0.0003431754,0.0001658847,0.001215338,0.0009260674,0.0001194823,0.0001094124,0.00170357,0.0001782198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002098654,"about_ca_system_score_gemma":0.0002973082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001486725,"about_ca_topic_score_gemma":0.00002920574,"domain_scores_codex":[0.9961869,0.0001518851,0.0005523794,0.0007575901,0.001398555,0.000952694],"domain_scores_gemma":[0.9972726,0.000827609,0.0001582626,0.0006406945,0.0005175822,0.0005832337],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001681228,0.0001479689,0.006410505,0.0002556688,0.0002683389,0.0002327049,0.003199369,1.571715e-7,0.9752675,0.0001236932,0.003323264,0.009089656],"study_design_scores_gemma":[0.025272,0.0119742,0.02065001,0.003862038,0.0003448451,0.0009439088,0.002897011,0.0002590298,0.7406715,0.0001824947,0.192012,0.0009308965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793535,0.007130952,0.000683718,0.005250425,0.001746605,0.001425064,0.00001438935,0.0002387002,0.004156649],"genre_scores_gemma":[0.9817162,0.0003608137,0.005466819,0.003791113,0.006612626,0.00005941275,0.0001392969,0.0001331129,0.001720579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2345959,"threshold_uncertainty_score":0.999902,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2901850955","doi":"10.1038/s41591-018-0266-5","title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Spinal Cord Injury BC","funders":"Horizon 2020 Framework Programme; BC Cancer Foundation; Krebsliga Beider Basel","keywords":"T-cell receptor; CD8; Immune system; Tumor-infiltrating lymphocytes; Cancer research; Cytotoxic T cell; Infiltration (HVAC); Repertoire; T cell; Biology; Pathology; Immunology; Medicine; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.01179061139679425,"gpt":0.3190317624480587,"spread":0.3072411510512644,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008102405,0.0001458877,0.0004313963,0.0001457033,0.00007971357,0.000004296861,0.0001583911,0.0001834466,0.001126795],"category_scores_gemma":[0.0006791346,0.00008488406,0.00003417408,0.000691019,0.0009000367,0.00004779548,0.00007291714,0.001260953,9.420823e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002471824,"about_ca_system_score_gemma":0.0002755584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001680473,"about_ca_topic_score_gemma":0.0008931273,"domain_scores_codex":[0.9985125,0.00009380475,0.0002563506,0.0002987966,0.0005529578,0.0002855884],"domain_scores_gemma":[0.9989509,0.0001097061,0.00009559849,0.000531712,0.0001980701,0.0001140128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005895226,0.00008563989,0.02050743,0.0001985798,0.00003515713,0.00005662297,0.0008226534,3.392669e-7,0.9665691,0.0004880124,0.004858501,0.005788419],"study_design_scores_gemma":[0.009596151,0.00282222,0.2199176,0.003556886,0.0001268967,0.0004390162,0.0007141692,0.0002873403,0.7170351,0.00138148,0.04383531,0.0002877859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739515,0.0009032695,0.000003841423,0.003755949,0.0003774585,0.0004661581,0.000003924537,0.00001902428,0.02051894],"genre_scores_gemma":[0.9937781,0.00004235481,0.0000673184,0.001374311,0.0008661462,0.00001093219,0.000005718353,0.00002134341,0.003833785],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.249534,"threshold_uncertainty_score":0.9997863,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2892758519","doi":"10.1038/s41591-018-0146-z","title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":567,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"CD19; Chimeric antigen receptor; Loss of heterozygosity; Biology; Antigen; Cancer research; Mutation; Immunology; Gene; Genetics; T cell; Allele; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01147386622342116,"gpt":0.3115330090825917,"spread":0.3000591428591705,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006145802,0.0002459981,0.0008534596,0.0005259822,0.00002656971,0.000002090845,0.0003007014,0.0004463572,0.003674824],"category_scores_gemma":[0.0001899909,0.0001731906,0.0001068853,0.0009445762,0.0006544208,0.00003169872,0.00005600836,0.0006236249,0.00001237435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002321512,"about_ca_system_score_gemma":0.0004822501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002912637,"about_ca_topic_score_gemma":0.0000356927,"domain_scores_codex":[0.9975026,0.00009474924,0.0005706943,0.0003727447,0.001037887,0.0004213037],"domain_scores_gemma":[0.9983683,0.0001581876,0.0001727156,0.0006367713,0.0004918511,0.0001722033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001739644,0.0001202676,0.01258963,0.000111327,0.0003007381,0.0001884194,0.001242759,0.000002813731,0.9760619,0.0003221895,0.0009989311,0.006321376],"study_design_scores_gemma":[0.011388,0.004931884,0.1315388,0.0006618403,0.00009167576,0.0002019963,0.0001821429,0.0005327331,0.8427359,0.002538651,0.004994619,0.0002017368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900644,0.003905974,0.0008968255,0.0008631236,0.0004829726,0.0007064844,0.00001788655,0.00002814872,0.003034129],"genre_scores_gemma":[0.9937488,0.002015161,0.001754672,0.0007346844,0.0006394442,0.00001176984,0.00002581516,0.00005127351,0.001018328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.133326,"threshold_uncertainty_score":0.997236,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2766745670","doi":"10.1182/blood-2017-07-793760","title":"Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Juno Therapeutics; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Washington State University","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; CD19; Antigen; Immunology; Virology; Cancer research; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.03004911792305832,"gpt":0.3166894952938824,"spread":0.286640377370824,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002074962,0.0001444037,0.0003347387,0.0001309509,0.0002790803,0.00003868082,0.0003289296,0.00009741773,0.002044236],"category_scores_gemma":[0.00006995127,0.0001348207,0.0001517222,0.0001401857,0.0002085675,0.00006423899,0.00005869888,0.0002211962,0.0001243641],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001791631,"about_ca_system_score_gemma":0.0001258281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003987299,"about_ca_topic_score_gemma":0.00001094149,"domain_scores_codex":[0.9988654,0.00005215276,0.0002699392,0.0002526919,0.0002884934,0.0002713097],"domain_scores_gemma":[0.998094,0.00005655226,0.0002155254,0.001335897,0.0001890324,0.000109046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001049997,0.001197132,0.06875755,0.00003732231,0.0002108351,0.000003038965,0.0001890321,0.000001240238,0.9228965,0.00006472454,0.0004913266,0.006046324],"study_design_scores_gemma":[0.008861482,0.0005970226,0.3426547,0.00005028644,0.00006727065,0.00003280274,0.000034728,0.00004283021,0.6345121,0.0001459162,0.01280572,0.0001951973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8989978,0.000643845,0.0001049707,0.0003704591,0.0001139045,0.0006050103,0.00001790796,0.00007313865,0.09907297],"genre_scores_gemma":[0.9939256,0.001009539,0.0005428556,0.00009438502,0.0001276976,0.00004350717,0.0000417076,0.00004458531,0.00417012],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2883844,"threshold_uncertainty_score":0.998868,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2602369513","doi":"10.1200/jco.2016.71.3024","title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Fludarabine; Lymphoma; Chemotherapy; Chimeric antigen receptor; Follicular lymphoma; Cyclophosphamide; Mantle cell lymphoma; Gastroenterology; Internal medicine; Immunology; T cell; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.1467258729733652,"gpt":0.4606296926420553,"spread":0.3139038196686901,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004436018,0.0002834123,0.002527618,0.0001782927,0.0002903449,0.00005981677,0.0007773984,0.0007566557,0.004709302],"category_scores_gemma":[0.0077354,0.0001846071,0.000488243,0.0001827307,0.0008413096,0.00021951,0.0001736011,0.00148638,0.00007501755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004723011,"about_ca_system_score_gemma":0.002154152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009041276,"about_ca_topic_score_gemma":0.00007514347,"domain_scores_codex":[0.9950361,0.0009295449,0.002194897,0.0003898526,0.0008748884,0.0005747576],"domain_scores_gemma":[0.9903299,0.002421871,0.004463499,0.000758375,0.001099145,0.0009271677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006118509,0.004685826,0.3497611,0.00004230715,0.002879595,0.002133085,0.000313883,0.000004859669,0.3223482,0.000007738519,0.1996468,0.1120581],"study_design_scores_gemma":[0.01762193,0.01208693,0.7664518,0.0006346211,0.0002656098,0.0001510812,0.0001807082,0.00002572074,0.01085899,0.00004332843,0.1914572,0.0002221023],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774203,0.0001584937,0.00002800385,0.01756845,0.001899472,0.0003076817,0.00004653548,0.00002383574,0.00254725],"genre_scores_gemma":[0.9800022,0.001018142,0.0004706033,0.00150767,0.001352534,0.000002984335,0.000008816227,0.00006496281,0.01557214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4166907,"threshold_uncertainty_score":0.9962005,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3201013983","doi":"10.1016/s1470-2045(21)00375-2","title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Cytokine release syndrome; Oncology; Hematopoietic stem cell transplantation; Chimeric antigen receptor; Cohort; Transplantation; Clinical trial; Immunotherapy; Cancer; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1492125776892486,"gpt":0.4590593045005727,"spread":0.3098467268113241,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001293543,0.0002696253,0.001631843,0.000106055,0.00007406018,0.00003009968,0.000648835,0.0002193903,0.001945349],"category_scores_gemma":[0.001001262,0.0001586251,0.00007877134,0.0004687956,0.0003549483,0.00009412426,0.0005129078,0.0007281473,0.00004663755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004286454,"about_ca_system_score_gemma":0.001029442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007880131,"about_ca_topic_score_gemma":0.000992425,"domain_scores_codex":[0.9957583,0.001626735,0.0008720403,0.000587235,0.0005590272,0.0005966816],"domain_scores_gemma":[0.9957576,0.001878999,0.0006230221,0.001173286,0.0003777102,0.0001894112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04795652,0.09310974,0.7945369,0.0000778922,0.0005311684,0.003028312,0.001645056,8.913502e-7,0.001922937,0.000002654581,0.0006999822,0.05648797],"study_design_scores_gemma":[0.24618,0.03607895,0.7128395,0.0001552739,0.0002901174,0.00003778403,0.000648556,0.00002352672,0.0008902606,0.000006918991,0.002641767,0.0002072909],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925367,0.0002697322,0.000003830933,0.000801186,0.0003061876,0.002553468,0.00002689681,0.00002897565,0.003473032],"genre_scores_gemma":[0.9915817,0.0002729837,0.000530128,0.001358816,0.0001711206,0.00009773017,0.00006430573,0.0000589181,0.005864256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1982235,"threshold_uncertainty_score":0.998967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4226068368","doi":"10.1038/s41568-022-00466-1","title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","year":2022,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":513,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Victoria; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Immunotherapy; Immunology; Immune system; Cancer immunotherapy; Biology; T cell; Immune checkpoint; Antigen; Cancer research; Context (archaeology); Autoimmunity","retraction":null,"screen_n_in":null,"score":{"opus":0.3309784990381246,"gpt":0.5148692975168264,"spread":0.1838907984787018,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003924296,0.0009912066,0.005838198,0.0003066055,0.0002369315,0.0000950067,0.0005731197,0.001547992,0.03511021],"category_scores_gemma":[0.0004454471,0.0006087865,0.002419734,0.0006366189,0.0002724474,0.00006232337,0.0003527192,0.00837628,0.00004642667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008110777,"about_ca_system_score_gemma":0.001945416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003742335,"about_ca_topic_score_gemma":0.000006992943,"domain_scores_codex":[0.9931826,0.002195641,0.00187057,0.001079167,0.0008748033,0.0007972335],"domain_scores_gemma":[0.99613,0.0013797,0.0009362896,0.001008182,0.0001185067,0.0004273015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006762158,0.00009409634,0.000003586,0.01453669,0.0007971381,0.0001523052,0.00002575975,3.602717e-8,0.00007689542,0.0001358604,0.002414559,0.9816955],"study_design_scores_gemma":[0.0004785999,0.0006836999,0.000007594943,0.01225804,0.00215327,0.0005164727,0.00004428181,0.000003466826,0.000006583452,0.00006344958,0.9832382,0.0005462989],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000007337421,0.9926795,0.000006126428,0.0002053275,0.0009388109,0.003764775,0.0001717228,0.00009896621,0.002127473],"genre_scores_gemma":[0.000005266652,0.9921322,0.0002588666,0.001297194,0.001016677,0.001140524,0.0002206425,0.0001810659,0.003747568],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9811491,"threshold_uncertainty_score":0.9997482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3157520262","doi":"10.1126/scitranslmed.abe7378","title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","year":2021,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":495,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"UCSF Foundation; National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; University of California, San Francisco; Parker Institute for Cancer Immunotherapy; Howard Hughes Medical Institute","keywords":"Antigen; Chimeric antigen receptor; Cancer research; Priming (agriculture); Biology; Cytotoxic T cell; Immunology; T cell; Glioma; Medicine; Immune system; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.0760524279981797,"gpt":0.3398417503001824,"spread":0.2637893223020027,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001056465,0.0001335811,0.0003720269,0.0004067741,0.00007957435,0.00001007092,0.000147071,0.00004506825,0.0006259081],"category_scores_gemma":[0.0001536378,0.0001124971,0.00005318422,0.001055008,0.001354694,0.0001521897,0.00004201647,0.0001935483,0.000003123099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007164725,"about_ca_system_score_gemma":0.0003416589,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004342907,"about_ca_topic_score_gemma":0.0003041645,"domain_scores_codex":[0.9975291,0.00005998404,0.0003574234,0.0004712425,0.001272076,0.0003101995],"domain_scores_gemma":[0.9989135,0.0002960049,0.00005618874,0.0002551816,0.0002882954,0.0001908738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0001500993,0.0001106728,0.01661462,0.0001603869,0.0000147361,0.00007729106,0.001919477,0.00005383002,0.9606267,0.001128034,0.000002656448,0.01914155],"study_design_scores_gemma":[0.00536787,0.001370616,0.5286596,0.001463442,0.00006480398,0.000540162,0.00439336,0.005223248,0.4506828,0.001303219,0.0006337972,0.0002970857],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807355,0.0037434,0.00009026688,0.007524819,0.00009985604,0.0002234822,0.000006948177,0.00001370691,0.00756203],"genre_scores_gemma":[0.9974717,0.001076766,0.001065554,0.00008394668,0.0001176175,0.00000476219,0.000003025518,0.00001022605,0.0001664268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.512045,"threshold_uncertainty_score":0.6853254,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3134659811","doi":"10.1038/s41573-021-00155-y","title":"Beyond immune checkpoint blockade: emerging immunological strategies","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":477,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Immune checkpoint; Blockade; Cancer immunotherapy; Medicine; T cell; Immune system; Immunology; Cancer research; Receptor; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04113483083086296,"gpt":0.3922663755111197,"spread":0.3511315446802568,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.002458652,0.001514274,0.0090652,0.0005135267,0.0002032805,0.0005324635,0.001008993,0.002024451,0.004920062],"category_scores_gemma":[0.0008716736,0.0009872231,0.005556257,0.001847425,0.0003115439,0.0004868993,0.000764458,0.009165711,0.0004197811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000752004,"about_ca_system_score_gemma":0.002211315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002204167,"about_ca_topic_score_gemma":0.000008399574,"domain_scores_codex":[0.9918909,0.001409059,0.002675713,0.001624649,0.001229408,0.001170255],"domain_scores_gemma":[0.9954157,0.0004925079,0.001021887,0.002537886,0.0002487928,0.0002831525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003525584,0.0002786053,0.000001078633,0.04428711,0.0009448514,0.0005236643,0.00006710513,1.679479e-7,0.0003662962,0.0007170062,0.002445896,0.9503329],"study_design_scores_gemma":[0.0004916368,0.00008393684,0.000004022353,0.06320865,0.002039768,0.0008291233,0.0001541133,6.410844e-7,0.00009020486,0.00008083908,0.9322003,0.0008168195],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000196094,0.9801202,0.00001059164,0.0004236287,0.001175761,0.004026526,0.00007289935,0.0001274809,0.01402325],"genre_scores_gemma":[0.000006036737,0.9598526,0.0002862167,0.0001683445,0.001547881,0.0005687121,0.001442724,0.0002277158,0.03589981],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9495161,"threshold_uncertainty_score":0.9997606,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2303852857","doi":"10.1172/jci82771","title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":476,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of British Columbia; Canadian Blood Services","keywords":"Chimeric antigen receptor; Immunology; Antigen; Immunotherapy; Human leukocyte antigen; Transplantation; Immune system; Cell therapy; Adoptive cell transfer; Major histocompatibility complex; Biology; Graft-versus-host disease; T cell; Medicine; Stem cell; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1053797030762472,"gpt":0.3739260898684617,"spread":0.2685463867922145,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002531396,0.0001659544,0.0006377936,0.0002005826,0.00005639295,0.00003012657,0.0001722358,0.000197254,0.002123069],"category_scores_gemma":[0.0004080264,0.00009104595,0.0002540784,0.0003890389,0.0005326421,0.0002375161,0.00002341914,0.0004963729,0.0001377565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009273122,"about_ca_system_score_gemma":0.0006991338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003241211,"about_ca_topic_score_gemma":0.000001486067,"domain_scores_codex":[0.9967684,0.0003950458,0.001435448,0.0002571303,0.0008796581,0.0002643848],"domain_scores_gemma":[0.996884,0.0004530374,0.0008857495,0.0003622926,0.0008102794,0.0006046167],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001439528,0.0001399466,0.05430578,0.00001359795,0.0002032254,0.00004941496,0.00007101426,0.000005215957,0.8823624,0.00004063474,0.01680805,0.0445612],"study_design_scores_gemma":[0.007075466,0.003472198,0.2285581,0.0007244016,0.00007985451,0.0002000637,0.0000440653,0.00006134022,0.5624907,0.0002775326,0.1967698,0.0002465585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928474,0.0003751809,0.0006197025,0.004884053,0.0005737154,0.0002629349,0.000002721655,0.00002471574,0.0004095186],"genre_scores_gemma":[0.967007,0.00438352,0.0161649,0.001352565,0.003529114,0.000004751862,0.000008869924,0.00008024821,0.007469044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3198717,"threshold_uncertainty_score":0.9987891,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141410122","doi":"10.1158/1078-0432.ccr-07-0674","title":"Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":466,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; Immunology; Adoptive cell transfer; Cancer research; T cell; Homing (biology); Medicine; Ex vivo; Systemic administration; CD28; Immunotherapy; Leukemia; In vivo; Biology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.1267420617162681,"gpt":0.4841363589671988,"spread":0.3573942972509307,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.01182176,0.0003477754,0.0009728475,0.0006329559,0.0002935792,0.0001070407,0.000848869,0.0006184974,0.007633899],"category_scores_gemma":[0.001101835,0.0002931771,0.0004673704,0.00177066,0.001643009,0.00007517867,0.0004421939,0.002738963,0.00165706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002058638,"about_ca_system_score_gemma":0.003537073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004197487,"about_ca_topic_score_gemma":0.0001091606,"domain_scores_codex":[0.9911961,0.0008524598,0.001573085,0.001216313,0.002904716,0.002257342],"domain_scores_gemma":[0.9919121,0.003335268,0.000137338,0.00138642,0.001338551,0.001890336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01101208,0.0006246184,0.02477793,0.000497378,0.001019823,0.002137868,0.0002098579,0.00003249083,0.8142546,0.0001365388,0.03509162,0.1102052],"study_design_scores_gemma":[0.03181124,0.0116791,0.1960239,0.002382375,0.0008267016,0.0009118053,0.0005273339,0.004486745,0.3772839,0.0007110121,0.3713591,0.001996801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845899,0.003192235,0.0006132639,0.00129638,0.001121613,0.001945578,0.00004053016,0.0001784249,0.007022093],"genre_scores_gemma":[0.9621128,0.007220078,0.0006776449,0.000808335,0.003151006,0.0001939287,0.0000310269,0.0001602522,0.02564496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4369707,"threshold_uncertainty_score":0.999952,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2955729565","doi":"10.1161/circulationaha.118.034497","title":"Myocarditis in the Setting of Cancer Therapeutics","year":2019,"lang":"en","type":"review","venue":"Circulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; Ted Rogers Centre for Heart Research; Canada Research Chairs; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research","keywords":"Medicine; Myocarditis; Clinical trial; Cancer; Incidence (geometry); Disease; Internal medicine; Intensive care medicine; Oncology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.151932586011727,"gpt":0.439782482553563,"spread":0.287849896541836,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005585135,0.0001353261,0.0007597888,0.0001618943,0.00001698899,0.00001126427,0.0001230977,0.0001849021,0.0003279326],"category_scores_gemma":[0.00002385782,0.00008888845,0.0002887282,0.0004514375,0.00002648945,0.00002314937,0.00001590425,0.000371592,0.00002274171],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002027059,"about_ca_system_score_gemma":0.0003085878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009678307,"about_ca_topic_score_gemma":0.0000164443,"domain_scores_codex":[0.9986958,0.0002234187,0.000356347,0.0001783871,0.0003945233,0.0001515099],"domain_scores_gemma":[0.9990547,0.0002572041,0.0001826978,0.0004192697,0.00007022305,0.00001588395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000003569978,0.00001595859,0.003903677,0.008126684,0.0001326012,0.000002435717,0.000278148,0.00001013532,0.00004028128,0.00002746213,0.00002693304,0.9874321],"study_design_scores_gemma":[0.0002877232,0.00001826586,0.0167032,0.007336893,0.0007213579,0.00002698339,0.00003933374,0.0001509503,0.000002707335,0.00002464652,0.9745861,0.0001018462],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004174475,0.9953607,0.0000145112,0.00009054762,0.0001347697,0.001416194,0.0000130095,0.000008156901,0.002544691],"genre_scores_gemma":[0.004280522,0.9949905,0.000009198725,0.00008397333,0.0002461405,0.00008448678,0.0001139717,0.00003483085,0.0001563459],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9873303,"threshold_uncertainty_score":0.3624766,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.04388713937975811,"gpt":0.3604510344685047,"spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001037941,0.0001752809,0.0008325018,0.0001819736,0.0001343032,0.000007697706,0.0002469668,0.00006305294,0.0009686145],"category_scores_gemma":[0.0001644679,0.0001084175,0.00004718837,0.000591484,0.0002261524,0.00003652408,0.000237189,0.0004016471,0.000003470654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006856475,"about_ca_system_score_gemma":0.0002938883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001826802,"about_ca_topic_score_gemma":0.0001675059,"domain_scores_codex":[0.997354,0.0009068666,0.000416166,0.0003692432,0.00053079,0.0004228957],"domain_scores_gemma":[0.9982909,0.000692657,0.0001976274,0.0006369515,0.00009158453,0.00009027102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4685131,0.09002679,0.25896,0.0001361704,0.0008119175,0.001873121,0.01520236,0.0001249807,0.01637679,0.00004844667,0.0005647847,0.1473615],"study_design_scores_gemma":[0.3183252,0.0727651,0.5026208,0.00006065432,0.0002318841,0.0001035211,0.00402817,0.0003231793,0.0001845417,0.00001095796,0.101091,0.0002550238],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955609,0.0002536065,0.000004515393,0.0005407225,0.0001050457,0.002364668,0.00002981966,0.0000307758,0.001109952],"genre_scores_gemma":[0.9986775,0.0001100402,0.0001148957,0.0002038768,0.00008862918,0.00006504554,0.00005946916,0.00003643501,0.0006440926],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2436609,"threshold_uncertainty_score":0.9999446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2802513889","doi":"10.1038/s41568-018-0009-4","title":"Oncolytic viruses as engineering platforms for combination immunotherapy","year":2018,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Victoria; University of Ottawa; BC Cancer Agency; Ottawa Hospital; University of British Columbia; Ontario Institute for Cancer Research","funders":"","keywords":"Oncolytic virus; Cytotoxic T cell; Immunotherapy; Immune checkpoint; Immune system; Cancer immunotherapy; Antigen; Melanoma; Cancer; Cancer research; Immunology; Priming (agriculture); T cell; Medicine; Biology; Internal medicine; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.08964551249103939,"gpt":0.4638803930683432,"spread":0.3742348805773038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001152083,0.0007478745,0.003551291,0.000419825,0.00009370843,0.00006310808,0.0004493635,0.001384345,0.003017918],"category_scores_gemma":[0.0005876127,0.0005048931,0.001589722,0.0008096289,0.000068745,0.0001187984,0.00005674804,0.001929713,0.0002873461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001719225,"about_ca_system_score_gemma":0.001129421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002794156,"about_ca_topic_score_gemma":0.0000143966,"domain_scores_codex":[0.996956,0.00005647156,0.001044073,0.0007138652,0.0006256032,0.000604002],"domain_scores_gemma":[0.9975475,0.0004341931,0.0005335725,0.0009355841,0.0003545114,0.0001946166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008631118,0.00006556095,0.000001187643,0.05331058,0.0005140808,0.000005197199,0.00003003433,9.826825e-8,0.00004579241,0.0002318088,0.01252484,0.9331845],"study_design_scores_gemma":[0.001118943,0.0003934676,0.000001463857,0.05750165,0.0008835904,0.00007583854,0.000001499995,0.00001269607,0.0000559467,0.00004330081,0.9394582,0.0004533996],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000005248852,0.9882796,0.00005907678,0.00006151491,0.00140383,0.008901496,0.00007427891,0.0001014286,0.00111353],"genre_scores_gemma":[6.789702e-7,0.9828131,0.000472468,0.000835134,0.002220699,0.003859752,0.0002221158,0.0002692741,0.00930681],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9327311,"threshold_uncertainty_score":0.9999121,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3137447968","doi":"10.1200/jco.20.03175","title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Gastroenterology; Refractory (planetary science); Follicular lymphoma; Lymphoma; Rituximab; Adverse effect; CD20; Alemtuzumab; Oncology; T cell; Immunology; Immune system; Transplantation","retraction":null,"screen_n_in":null,"score":{"opus":0.2659444738081362,"gpt":0.5123547411190288,"spread":0.2464102673108926,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01296793,0.0003229704,0.002680075,0.0005304338,0.0001784643,0.00004956509,0.0004210974,0.0007482478,0.003099527],"category_scores_gemma":[0.01589971,0.0002385572,0.0008948226,0.0009527451,0.0003041443,0.0001702769,0.000216167,0.003278981,0.00003957582],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007590653,"about_ca_system_score_gemma":0.009032334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004031485,"about_ca_topic_score_gemma":0.00002275706,"domain_scores_codex":[0.9903271,0.002378209,0.004807657,0.000600286,0.001121412,0.000765394],"domain_scores_gemma":[0.9844342,0.01085221,0.002304085,0.0005396844,0.0009294188,0.0009403929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1589805,0.03203849,0.001714551,0.0001627403,0.0002284978,0.01080312,0.0003649379,0.00001363151,0.7414843,0.000007578538,0.004853024,0.04934863],"study_design_scores_gemma":[0.5129048,0.02436674,0.001736446,0.0006824234,0.0002910532,0.001211099,0.00224428,0.0006677249,0.01300595,0.00005160444,0.4424855,0.0003523663],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980907,0.001909403,0.0001347108,0.006260362,0.002631015,0.0005699631,0.00001134436,0.00002383802,0.007552407],"genre_scores_gemma":[0.9791636,0.005144499,0.005942306,0.001105571,0.003075272,0.00001000969,0.00002413299,0.00007525072,0.005459333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7284784,"threshold_uncertainty_score":0.9990205,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379375856","doi":"10.1056/nejmoa2301665","title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Confidence interval; Lymphoma; Oncology; Transplantation; Autologous stem-cell transplantation; Survival analysis; Surgery; Rituximab","retraction":null,"screen_n_in":null,"score":{"opus":0.03199120473262039,"gpt":0.3131821044199231,"spread":0.2811908996873027,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002644839,0.0001776761,0.0006793782,0.000683429,0.00003604716,0.000008979968,0.0001788702,0.00008161392,0.001835843],"category_scores_gemma":[0.0002637016,0.00010707,0.000077133,0.0009764982,0.0000920325,0.00006733509,0.00003570673,0.0004463858,0.00004255984],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001199954,"about_ca_system_score_gemma":0.0004840865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001336973,"about_ca_topic_score_gemma":0.0001620758,"domain_scores_codex":[0.9974955,0.0001409387,0.0005387116,0.0001749321,0.001184811,0.0004650938],"domain_scores_gemma":[0.9985206,0.0003400737,0.0001711735,0.0002545979,0.0002118074,0.0005017756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02037723,0.001573273,0.161751,0.0003526213,0.0004349058,0.02290768,0.006344575,0.00007797818,0.2147999,0.0001569656,0.0421505,0.5290733],"study_design_scores_gemma":[0.482251,0.008257372,0.1326782,0.001146237,0.0001875137,0.003083914,0.00182795,0.0003206374,0.006318482,0.000268477,0.3633893,0.0002709566],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9749553,0.001014789,0.0001773875,0.01052006,0.0004425137,0.000196898,0.000002540532,0.00002897984,0.01266154],"genre_scores_gemma":[0.9752706,0.001460984,0.0001420898,0.0004437774,0.003769672,0.000001822025,0.0000128707,0.00004329274,0.01885491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5288023,"threshold_uncertainty_score":0.9990766,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2911504656","doi":"10.1182/blood-2018-11-883710","title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Juno Therapeutics; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Celgene","keywords":"Medicine; CAR T-cell therapy; CD19; Internal medicine; Oncology; Immunology; T cell; Chimeric antigen receptor; Antibody; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01910421137190766,"gpt":0.2534960935338183,"spread":0.2343918821619106,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002325158,0.0003357751,0.0005268477,0.000215439,0.00004062232,0.00004025374,0.0001868838,0.0002022492,0.001508071],"category_scores_gemma":[0.00009980427,0.0002443121,0.0001303158,0.0004160965,0.00005756458,0.000141263,0.00005309979,0.0005854405,0.0001052027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001970042,"about_ca_system_score_gemma":0.0001392017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003554593,"about_ca_topic_score_gemma":0.0002836457,"domain_scores_codex":[0.9975819,0.0001916745,0.000320771,0.0005057814,0.0007262894,0.0006735965],"domain_scores_gemma":[0.9985991,0.0002791431,0.000139204,0.0004744429,0.000306015,0.0002021543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007567676,0.002938472,0.9012592,0.00005928744,0.0002180038,0.0000341282,0.002923455,0.000003773352,0.0915934,7.397785e-7,0.00006990718,0.0001428753],"study_design_scores_gemma":[0.03693793,0.002610318,0.7571425,0.0003034808,0.00009678229,0.000001131355,0.000530166,0.00002866695,0.2014216,0.000008724396,0.0004910869,0.0004275432],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906471,0.0001400099,5.732016e-7,0.00008227414,0.00007805332,0.00150884,0.00004186123,0.00006189974,0.007439411],"genre_scores_gemma":[0.9888986,0.0001011687,0.00003686623,0.0003618391,0.00004093626,0.00006700472,0.00008755716,0.0000976159,0.01030835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1441166,"threshold_uncertainty_score":0.9994047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3217544539","doi":"10.1016/j.cell.2021.11.016","title":"An NK-like CAR T cell transition in CAR T cell dysfunction","year":2021,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Stand Up To Cancer; National Cancer Institute; National Institutes of Health; Incyte; Parker Institute for Cancer Immunotherapy; Bayer Fund; American Cancer Society; Stand Up To Cancer Canada; AstraZeneca; Celgene; GlaxoSmithKline","keywords":"Chimeric antigen receptor; Biology; T cell; CD8; Cancer research; Mesothelin; T-cell receptor; Immunology; Cell biology; Antigen; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01910311781100935,"gpt":0.2763343176554929,"spread":0.2572311998444835,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003134264,0.0001996609,0.0003141595,0.0001899448,0.00006304055,0.00003666597,0.000103489,0.0002158288,0.004903749],"category_scores_gemma":[0.000007137132,0.0002100994,0.0001410004,0.0004829635,0.00005188639,0.0001228986,0.00002096664,0.0005156805,0.0003069399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002567745,"about_ca_system_score_gemma":0.0002780067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002670627,"about_ca_topic_score_gemma":0.0001392512,"domain_scores_codex":[0.9981021,0.000195168,0.0002846007,0.0005179092,0.0004486502,0.0004515517],"domain_scores_gemma":[0.9988562,0.00005364041,0.00004195344,0.0006150344,0.0001702822,0.000262879],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002682658,0.0006740131,0.0007516135,0.0003507955,0.000007871402,0.0004627498,0.001949176,0.0001853905,0.9919459,0.00000189867,0.0013974,0.002004933],"study_design_scores_gemma":[0.004079278,0.0005421311,0.001635333,0.00004548782,0.00006051134,0.00003357868,0.001848479,0.001448005,0.9509168,0.00003071349,0.03912889,0.00023082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9498404,0.001170621,0.0003195388,0.0002547067,0.0004069932,0.0004208295,0.00001347805,0.00007205975,0.04750143],"genre_scores_gemma":[0.9630064,0.0004642919,0.0002450215,0.0005365257,0.0003451224,0.00002607639,0.0002922641,0.0000639944,0.0350203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04102912,"threshold_uncertainty_score":0.9960059,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2023548208","doi":"10.1016/s0092-8674(00)00140-9","title":"Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis","year":2000,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":388,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; University of Alberta","funders":"","keywords":"Cytotoxic T cell; Granzyme B; Biology; Granzyme; Perforin; Cell biology; Granzyme A; Apoptosis; Molecular biology; Cancer research; Biochemistry; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.02864367029211161,"gpt":0.2806585660275285,"spread":0.2520148957354169,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003372671,0.0006131391,0.000822934,0.0002961653,0.0005142206,0.00008778509,0.0004819236,0.0004358926,0.05547773],"category_scores_gemma":[0.00005037211,0.0005777976,0.0005656017,0.0005865681,0.00009028782,0.0001931152,0.0001214594,0.0006604015,0.001849354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004878962,"about_ca_system_score_gemma":0.0002209977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001646804,"about_ca_topic_score_gemma":0.000003873098,"domain_scores_codex":[0.9959808,0.0001089391,0.0006809911,0.001106523,0.0008058324,0.00131689],"domain_scores_gemma":[0.9976733,0.0001826724,0.000150278,0.0009628334,0.0002945874,0.0007363002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002802121,0.000857675,0.0004478818,0.0006050567,0.000107811,0.00001212037,0.001999065,9.9641e-7,0.9756888,0.000004568626,0.01236209,0.005111868],"study_design_scores_gemma":[0.007227512,0.001273627,0.00057416,0.0001050528,0.00007963503,0.000008946807,0.000124217,0.00005287925,0.8750815,0.00003024425,0.1149018,0.0005404838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866781,0.0007736487,0.00001911328,0.0008072375,0.0005554555,0.002671905,0.0002153156,0.0002805607,0.007998664],"genre_scores_gemma":[0.8012269,0.001868637,0.001233536,0.0007091525,0.000700551,0.0003747448,0.0001613515,0.0002323543,0.1934928],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1854942,"threshold_uncertainty_score":0.9996673,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4309411030","doi":"10.1200/jco.22.00642","title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Lymphoblastic Leukemia; Refractory (planetary science); Oncology; Young adult; Pediatrics; Internal medicine; Leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.04583295466574167,"gpt":0.3860338722729347,"spread":0.3402009176071931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004600054,0.0001241949,0.001035525,0.0003728585,0.00004143703,0.00000692203,0.0002997279,0.0001858767,0.0004039257],"category_scores_gemma":[0.00156816,0.00007710081,0.0001851329,0.0005296888,0.0001826485,0.00008217071,0.0001162002,0.00188403,0.000003703128],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006048291,"about_ca_system_score_gemma":0.002818517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000109002,"about_ca_topic_score_gemma":0.0004405515,"domain_scores_codex":[0.9958494,0.0009158649,0.001849917,0.000203385,0.000913288,0.000268176],"domain_scores_gemma":[0.9960063,0.002215598,0.001123464,0.0002325396,0.0002596562,0.0001624064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2215448,0.002422152,0.748802,0.00002868431,0.0001818255,0.0009481128,0.0003524492,0.00003752514,0.00005908086,0.00002747891,0.0019766,0.02361927],"study_design_scores_gemma":[0.1640646,0.04032029,0.7919285,0.00002689845,0.0002828558,0.0001287042,0.000224897,0.0001311267,0.000003192513,0.0001453118,0.002658744,0.00008487225],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971026,0.000185433,0.000009465925,0.0009071719,0.0006431332,0.0005281889,0.000007967496,0.000002472317,0.0006135927],"genre_scores_gemma":[0.9971432,0.00130691,0.0002245841,0.000654456,0.0005389578,0.0000139326,0.000004313023,0.00002036826,0.00009327727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05748022,"threshold_uncertainty_score":0.8185277,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2917127842","doi":"10.1182/blood-2018-11-887067","title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Juno Therapeutics; University of British Columbia; Celgene; Fred Hutchinson Cancer Research Center","keywords":"Medicine; Fludarabine; Cyclophosphamide; Cytokine release syndrome; Cytokine; Immunology; Internal medicine; Immunotherapy; Gastroenterology; Chemotherapy; Immune system; Chimeric antigen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.005690642519163778,"gpt":0.2428028470836772,"spread":0.2371122045645135,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004886565,0.000244576,0.000342609,0.0002359123,0.00007879343,0.00005331181,0.0001812523,0.0001036203,0.0001573183],"category_scores_gemma":[0.0001057941,0.0001385636,0.00005228448,0.0006733315,0.0000722301,0.00006910333,0.00005349415,0.0001302131,0.0001900748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003111967,"about_ca_system_score_gemma":0.0004014479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003821838,"about_ca_topic_score_gemma":0.0001439682,"domain_scores_codex":[0.9978201,0.0002347599,0.0002275202,0.0004085432,0.0007383281,0.0005707986],"domain_scores_gemma":[0.9983054,0.0002916908,0.0001311596,0.0007491138,0.0002547661,0.0002678056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06436773,0.00109631,0.6300261,0.00003592719,0.000213895,0.000262902,0.001085484,0.00003388877,0.2993216,0.000001018228,0.0001768568,0.00337829],"study_design_scores_gemma":[0.03454584,0.006752065,0.8011017,0.0004426963,0.00007954845,0.00004074322,0.0001670837,0.00002824833,0.1556132,0.000001416988,0.001006369,0.0002210262],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967811,0.00005846937,0.000003208644,0.0002331276,0.00004230042,0.002034676,0.00001885735,0.00003806083,0.0007901627],"genre_scores_gemma":[0.9957189,0.00002624792,0.0001209308,0.0001880271,0.00004302089,0.00007432757,0.0000263942,0.00007196223,0.003730175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1710757,"threshold_uncertainty_score":0.565046,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2575232561","doi":"10.1126/scitranslmed.aag2196","title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","year":2017,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Bausch Health (Canada)","funders":"Ben and Catherine Ivy Foundation; National Cancer Institute; National Institute of Neurological Disorders and Stroke; Wellcome; Royal Society; Wellcome Trust","keywords":"Glioma; Cytotoxic T cell; Cancer research; Immunotherapy; Reporter gene; Medicine; Genetic enhancement; Gene; Pet imaging; Pathology; Immunology; Biology; Gene expression; Positron emission tomography; Immune system; Nuclear medicine; In vitro; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04301497310250961,"gpt":0.3738410366915573,"spread":0.3308260635890477,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002040305,0.0001277294,0.0003181894,0.000550899,0.0001969369,0.00001957757,0.0004025069,0.00002804558,0.00216626],"category_scores_gemma":[0.0002036459,0.00009821601,0.00006259282,0.0005049714,0.001803026,0.0002634636,0.00002225079,0.0001867357,0.000004721377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000707811,"about_ca_system_score_gemma":0.0004688694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002235411,"about_ca_topic_score_gemma":0.00002365848,"domain_scores_codex":[0.9973614,0.00002846534,0.0005123962,0.0003762465,0.001383264,0.000338249],"domain_scores_gemma":[0.9985925,0.0000710883,0.0002041391,0.0006669812,0.0003197475,0.0001455548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0003339835,0.00009858997,0.06070679,0.00002904864,0.000006798373,0.00007257379,0.0008523425,0.000005459478,0.8979748,0.0000683539,0.00004301581,0.0398082],"study_design_scores_gemma":[0.005492543,0.0003138501,0.7129175,0.0002699021,0.00001615554,0.0001303317,0.0001094566,0.002335758,0.2758324,0.001108409,0.001335238,0.0001384476],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971753,0.00186667,0.0003815716,0.01009522,0.0004075129,0.0005189025,0.000005831681,0.00001715363,0.01495412],"genre_scores_gemma":[0.997907,0.0001211871,0.001251123,0.0001093513,0.0001672451,0.00001189681,0.00001346923,0.00001347456,0.0004052061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6522107,"threshold_uncertainty_score":0.9987459,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2155493718","doi":"10.4049/jimmunol.1102757","title":"Substrate Rigidity Regulates Human T Cell Activation and Proliferation","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Common Fund; National Institutes of Health; National Eye Institute; York University; University of Pennsylvania","keywords":"CD28; Ex vivo; T cell; Materials science; Cytotoxic T cell; CD8; Cell biology; Cell growth; T-cell receptor; Priming (agriculture); Cell adhesion; Biophysics; Chemistry; Cell; In vitro; Biology; Immunology; Immune system; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.03637093820036858,"gpt":0.3153096164480318,"spread":0.2789386782476633,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001006611,0.00006315002,0.0001548743,0.0000882634,0.0001000728,0.00000953466,0.00006884005,0.00006875933,0.0003219768],"category_scores_gemma":[0.00004105478,0.00003800867,0.00003315321,0.00006942673,0.0001252516,0.0001646363,0.00002094258,0.0003553062,0.00000655426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005400321,"about_ca_system_score_gemma":0.00004294522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001540951,"about_ca_topic_score_gemma":0.000001731457,"domain_scores_codex":[0.9992433,0.0001945149,0.0002187721,0.0000361102,0.0001388587,0.0001684491],"domain_scores_gemma":[0.9993891,0.0001008677,0.0001851665,0.0001349106,0.0001459238,0.00004404282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006349433,0.0000892322,0.009435545,0.00001107113,0.00006870634,0.000001206028,0.0008409041,0.00000156028,0.9869331,0.0001180277,0.0001563066,0.001709372],"study_design_scores_gemma":[0.001007056,0.0005781193,0.2555117,0.00001872211,0.00004424794,0.0005205588,0.0002201182,0.000007977848,0.7405515,0.0003859847,0.001119498,0.0000345781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964826,0.001112235,0.00004927023,0.001145158,0.00008891134,0.000138229,2.062774e-7,0.000005510011,0.0009778744],"genre_scores_gemma":[0.9980025,0.0003793994,0.00005420277,0.00006064686,0.0002912376,0.000001029027,0.000001743633,0.000008745662,0.00120051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2463817,"threshold_uncertainty_score":0.352542,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2584913109","doi":"10.1172/jci89455","title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Peter MacCallum Cancer Centre","keywords":"Chimeric antigen receptor; Cancer research; Adenosine; T cell; CD8; Antigen; Adenosine A2A receptor; Immunology; Receptor; Chemistry; Medicine; Adenosine receptor; Biology; Pharmacology; Immune system; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1147817052941857,"gpt":0.4295939475704932,"spread":0.3148122422763074,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005168532,0.0001598,0.0006089759,0.00008647118,0.0004101944,0.0001619226,0.0005647771,0.0001841654,0.001792456],"category_scores_gemma":[0.009536851,0.00009791174,0.00036966,0.0001445002,0.00072909,0.0003339617,0.00008483187,0.001214296,0.0001684785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004984423,"about_ca_system_score_gemma":0.0004561623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001990091,"about_ca_topic_score_gemma":0.000001264067,"domain_scores_codex":[0.9966546,0.000465768,0.001556462,0.0002240208,0.0008261105,0.0002730491],"domain_scores_gemma":[0.9951717,0.001178838,0.002135939,0.0005335212,0.0005753466,0.0004046175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001119647,0.0003588737,0.1174664,0.00005911377,0.0001983025,0.00001602658,0.0004901883,0.00001855441,0.7841672,0.00002577839,0.04830845,0.04777141],"study_design_scores_gemma":[0.006603254,0.002980845,0.3483889,0.0007417554,0.0002139948,0.00004680171,0.0002941885,0.0006097345,0.3909094,0.0005105523,0.2483798,0.0003208673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736769,0.0007489386,0.00008357565,0.02216284,0.001578909,0.0003370822,0.000002024348,0.00001510386,0.001394582],"genre_scores_gemma":[0.9790823,0.003754917,0.005384133,0.001005931,0.006415747,0.000003905968,0.00001254099,0.00003896886,0.004301591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3932578,"threshold_uncertainty_score":0.9991201,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1574902133","doi":"10.1038/nri1257","title":"T-cell development made simple","year":2004,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Lymphopoiesis; Cell biology; Thymocyte; Extracellular matrix; Function (biology); Biology; Stem cell; Cellular differentiation; Receptor; Chemistry; T cell; Haematopoiesis; Immunology; Biochemistry; Gene; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.05349645198295755,"gpt":0.3988182439844727,"spread":0.3453217920015151,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00118141,0.001059004,0.006004905,0.00066082,0.0001389071,0.00003322783,0.0008820309,0.003380901,0.006636133],"category_scores_gemma":[0.0003746388,0.0007502059,0.001522182,0.001061692,0.000206236,0.00004758103,0.0003892873,0.006787135,0.004656053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001688314,"about_ca_system_score_gemma":0.003039025,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001060315,"about_ca_topic_score_gemma":0.000003828094,"domain_scores_codex":[0.9948633,0.0006656511,0.001770733,0.001075775,0.0005336382,0.001090861],"domain_scores_gemma":[0.9969083,0.0002445369,0.0006845054,0.001749119,0.0001859122,0.0002276204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002939968,0.0001886166,7.96778e-7,0.05830568,0.0005046154,0.0001471853,0.00003777243,1.116125e-8,0.000112778,0.00008912229,0.005105504,0.9354785],"study_design_scores_gemma":[0.0008897245,0.0001967982,0.000003684997,0.02661093,0.0006859532,0.001094409,0.000004159112,2.744924e-8,0.0001022959,0.0000306777,0.9698132,0.0005681668],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000001921599,0.9867931,0.00001456214,0.0001041355,0.0006650032,0.004614844,0.00001465985,0.0001207888,0.007671002],"genre_scores_gemma":[7.145483e-7,0.9701222,0.001593079,0.0003670277,0.0003959416,0.0006435478,0.001026941,0.0002103675,0.02564017],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9647077,"threshold_uncertainty_score":0.9994949,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2333997296","doi":"10.1038/nbt.3525","title":"Quality cell therapy manufacturing by design","year":2016,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"World Wildlife Fund Canada; University of Toronto","funders":"Health Canada; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Government of Canada; University of Pennsylvania","keywords":"Biopharmaceutical; Quality by Design; Quality (philosophy); Manufacturing process; New product development; Risk analysis (engineering); Good manufacturing practice; Computer science; Product (mathematics); Biochemical engineering; Process (computing); Population; Process development; Manufacturing engineering; Engineering; Medicine; Business; Biotechnology; Operations management; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02871814589402916,"gpt":0.334367134779287,"spread":0.3056489888852579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005059892,0.0001983577,0.0003261697,0.000223591,0.00005888125,0.000009339037,0.0003095591,0.001946454,0.002232337],"category_scores_gemma":[0.0001198085,0.000119127,0.0001033491,0.0001805625,0.0002433726,0.00004025677,0.00007626353,0.001191441,0.0001636355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001659808,"about_ca_system_score_gemma":0.00006973793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001639375,"about_ca_topic_score_gemma":0.000002095363,"domain_scores_codex":[0.9983773,0.0001138137,0.0002150596,0.0004800214,0.0003308449,0.0004829288],"domain_scores_gemma":[0.9987481,0.0002456818,0.00006961703,0.0007803924,0.00005430203,0.0001019405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004414046,0.00008629121,0.00017221,0.00001031803,0.00003395422,0.00001878285,0.00000986827,2.760462e-8,0.7503033,0.0001857864,0.01031049,0.2384275],"study_design_scores_gemma":[0.00171151,0.0003018869,0.0005046682,0.00001168014,0.000003434155,0.00002585565,0.00001062499,7.792181e-7,0.678528,0.0004754443,0.3183193,0.0001068629],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9097158,0.01009421,0.01024142,0.06115448,0.0004383446,0.001353719,0.00003326279,0.001047557,0.005921239],"genre_scores_gemma":[0.9775464,0.003087618,0.001926183,0.001149936,0.0001304367,0.00002749233,0.000006429158,0.0000473858,0.0160781],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3080088,"threshold_uncertainty_score":0.9993492,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2010618607","doi":"10.1016/j.stem.2008.09.001","title":"The Systematic Production of Cells for Cell Therapies","year":2008,"lang":"en","type":"review","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Heart and Stroke Foundation; University Health Network; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; John Simon Guggenheim Memorial Foundation","keywords":"Expediting; Bioprocess; Biomanufacturing; Biology; Biotechnology; Biochemical engineering; Cell therapy; Stem cell; Risk analysis (engineering); Engineering; Cell biology; Systems engineering; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.06763248157530957,"gpt":0.3315808366050735,"spread":0.263948355029764,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001295881,0.0007959089,0.003510977,0.000310676,0.0003341938,0.00006370911,0.0007405905,0.0005202251,0.000159473],"category_scores_gemma":[0.00002723649,0.0004704199,0.001734431,0.0005928797,0.0002878871,0.00005378857,0.0001132404,0.0007055904,0.000260155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003450716,"about_ca_system_score_gemma":0.0007587543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001227189,"about_ca_topic_score_gemma":0.00000270879,"domain_scores_codex":[0.9949965,0.0006472961,0.001767073,0.0008469259,0.0009618864,0.0007803419],"domain_scores_gemma":[0.9942951,0.001679731,0.001338948,0.002001274,0.0004749197,0.0002099997],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001126864,0.0004728751,6.221496e-7,0.8494973,0.0003074502,0.00001504801,0.0007081387,0.000001398798,0.005111546,0.000005937059,0.01133301,0.132434],"study_design_scores_gemma":[0.0007601249,0.0005294415,9.68428e-8,0.02535652,0.001303872,0.00007726531,0.0004753018,0.000009000837,0.02980146,0.000005593718,0.941287,0.0003943501],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008166937,0.9745192,0.00003223454,0.0000292504,0.001412494,0.01410986,0.00003165222,0.0000736494,0.009709977],"genre_scores_gemma":[0.00008339284,0.7663502,0.0001070963,0.00001015125,0.000480123,0.001052301,0.00004764883,0.0002113706,0.2316577],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.929954,"threshold_uncertainty_score":0.9997748,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2044365745","doi":"10.1038/nm1134","title":"Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells","year":2004,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institutes of Health","keywords":"BCL6; Corepressor; Cancer research; Biology; Psychological repression; Repressor; Lymphoma; Cell biology; B cell; Transcription factor; Gene; Germinal center; Genetics; Immunology; Gene expression; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.01922761632051356,"gpt":0.2900272092528044,"spread":0.2707995929322908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007701476,0.0002963907,0.0006010107,0.000460058,0.00005184001,0.00001391266,0.0002071439,0.0004310265,0.002442039],"category_scores_gemma":[0.00009024229,0.0002303808,0.00009315616,0.0005571016,0.0002606805,0.00007587927,0.00004206261,0.001091583,0.00005789965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004254571,"about_ca_system_score_gemma":0.0001830264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008886264,"about_ca_topic_score_gemma":0.00004135057,"domain_scores_codex":[0.9975575,0.00007558472,0.0004638986,0.0005776269,0.0008432212,0.0004821781],"domain_scores_gemma":[0.9988727,0.0001711425,0.00007112177,0.0004098611,0.0001457416,0.0003294266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007524528,0.0003150486,0.0002285569,0.0001371087,0.00002793093,0.0003730088,0.0008760204,0.0000017436,0.9871638,0.001754351,0.001253529,0.007116463],"study_design_scores_gemma":[0.06164305,0.004431543,0.04204903,0.002817878,0.0001685209,0.001299763,0.001402439,0.00003917922,0.8093811,0.01930384,0.05668326,0.0007803411],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965354,0.01310537,0.0008492953,0.007305467,0.0006632726,0.0008988594,0.00001453343,0.00006972485,0.01173949],"genre_scores_gemma":[0.9860132,0.002376665,0.001515826,0.001946386,0.0005491299,0.00002402092,0.0000446371,0.00004742372,0.007482685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1777826,"threshold_uncertainty_score":0.9984699,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4221044986","doi":"10.1038/s41591-022-01731-4","title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemoimmunotherapy; Oncology; Cytokine release syndrome; Phases of clinical research; Lymphoma; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer; Rituximab","retraction":null,"screen_n_in":null,"score":{"opus":0.02147039958810337,"gpt":0.3415673981146957,"spread":0.3200969985265923,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00381554,0.0004709228,0.0009719207,0.000546395,0.0005779178,0.00002016081,0.0007344899,0.000397447,0.02376741],"category_scores_gemma":[0.0007745428,0.0002923662,0.0002590406,0.00146785,0.0002718299,0.00006187431,0.0002669104,0.003310421,0.00006071825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005783987,"about_ca_system_score_gemma":0.0004603553,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000886745,"about_ca_topic_score_gemma":0.0002268306,"domain_scores_codex":[0.9945062,0.0006697564,0.0007690532,0.0007827297,0.002352317,0.0009199539],"domain_scores_gemma":[0.9970493,0.000879202,0.0002659836,0.001304695,0.0001671449,0.0003336361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4365458,0.02829088,0.002197437,0.0001882071,0.0007703573,0.003526784,0.007533842,0.00004949286,0.06248479,0.0009104844,0.1279146,0.3295873],"study_design_scores_gemma":[0.4147342,0.01269776,0.0008754396,0.00004716363,0.0001116345,0.0001242055,0.0006361334,0.0002926471,0.005333923,0.0003793213,0.5645286,0.0002389664],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9435934,0.01777083,0.00002817847,0.0266247,0.00201134,0.003069433,0.0001022562,0.000123374,0.006676436],"genre_scores_gemma":[0.96198,0.005406964,0.00003029411,0.008045199,0.003747986,0.0004529779,0.0003623013,0.0001132529,0.01986105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.436614,"threshold_uncertainty_score":0.9999529,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2734515449","doi":"10.1016/j.ymthe.2017.07.004","title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Research and Development; Graduate Women – New South Wales; Northwest University; Department of Health and Social Care; NIH Clinical Center; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; Government of Canada; Geoffrey Beene Cancer Research Center; National Institute for Health and Care Research; National Cancer Research Institute","keywords":"Chimeric antigen receptor; CD19; Lymphoma; Medicine; Antigen; Receptor; Immunology; B cell; Cell; Cancer research; Biology; T cell; Antibody; Internal medicine; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.02657168721673962,"gpt":0.3032861052003658,"spread":0.2767144179836261,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004459816,0.0004123437,0.0006724916,0.0002170534,0.0003661113,0.0001199203,0.0005951587,0.0002346456,0.003303402],"category_scores_gemma":[0.00003686666,0.0003431949,0.0004338739,0.0002186155,0.0002380022,0.000147556,0.0001118197,0.0002593802,0.0001510668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008287132,"about_ca_system_score_gemma":0.0001911645,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001049977,"about_ca_topic_score_gemma":0.000003879043,"domain_scores_codex":[0.9971335,0.0002462933,0.0005291575,0.0006147669,0.00081201,0.0006642688],"domain_scores_gemma":[0.996892,0.00005344045,0.0003850145,0.002100952,0.0002626045,0.0003059627],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001682501,0.00301592,0.01856106,0.00005066703,0.000155317,0.0001377109,0.0006138217,8.533669e-7,0.9609182,0.000008482669,0.000364437,0.01449106],"study_design_scores_gemma":[0.01835688,0.0006894323,0.09450651,0.00007687023,0.00002062369,0.00001489866,0.00004722856,0.0001472384,0.8258918,0.00003034974,0.05988183,0.0003363382],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896389,0.004138137,0.001048121,0.000782164,0.0002253293,0.001269292,0.00005892547,0.00007234402,0.002766743],"genre_scores_gemma":[0.9841714,0.009282957,0.0006619592,0.0007997698,0.0001667544,0.00007353735,0.0001231404,0.0001459613,0.004574526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1350264,"threshold_uncertainty_score":0.999902,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}